文献速递妇产影像泌尿生殖MR

MRI时机选择用于宫颈癌放化疗早期治疗反应预测

Timing of MRI for early treatment response prediction of chemoradiotherapy in uterine cervical cancer.
PubMed 文献 · Eur J Radiol · 2025-11-23

一项纳入15例IIB-IIIB期宫颈癌患者的先导研究,于治疗前及治疗开始后3周、5周、12周行四次MRI,记录肿瘤最大径、DWI可见性及ADC值。基线肿瘤大小联合5周DWI可见肿瘤预测预后分组的AUC为0.83,提示该组合可能预测放化疗结局。

要点

  • 基线MRI肿瘤大小联合治疗5周时DWI可见肿瘤,预测预后分组AUC=0.83。
  • 5周时高b值DWI可见肿瘤预测预后分组的敏感度83%(5/6)、特异度63%(5/8)。
  • 加入ADC值未提高任何时间点的预测价值。

核心结论

  • 该先导研究提示,基线MRI肿瘤大小联合5周时DWI肿瘤可见性可能预测宫颈癌放化疗结局。

研究设计与样本

  • 先导研究纳入15例FIGO 2009 IIB-IIIB期拟行放化疗的宫颈癌患者,所有患者于基线及治疗开始后3周、5周、12周行四次MRI检查。

关键影像表现/征象

  • 预后不良组7/15例在全部四个时间点肿瘤均大于预后良好组8/15例,肿瘤大小随时间点变化但组间无显著差异;12周时预后良好组无患者、预后不良组2/7例DWI仍可见肿瘤。

诊断标准与关键数值

  • 5周时高b值DWI可见肿瘤预测预后分组的敏感度83%(5/6)、特异度63%(5/8);基线肿瘤大小联合5周DWI可见肿瘤的AUC=0.83。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文称该研究为先导研究(pilot study)。
  • 原文结论用「may predict」表述,提示可能预测放化疗结局。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To explore the optimal use of MRI including time point to predict early treatment response during definitive chemoradiotherapy in cervical carcinoma.

METHODS: Pilot study including 15 patients with cervical carcinoma stage IIB-IIIB (FIGO 2009) scheduled for chemoradiotherapy. All patients underwent four MRI examinations (at baseline, 3 weeks, 5 weeks, and 12 weeks after treatment start). Maximum tumor size, size change (Δsize), visibility on diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) mean and change in ADC (ΔADC) at the different time points were recorded.

RESULTS: 7/15 patients relapsed during the study period, referred to as "poor prognosis" (PP) and the remaining 8/15 are referred to as "good prognosis" (GP). At all four time points, the tumors in the PP patients were larger than in the GP patients. Tumor size did change between the time point but this was not significant between the groups. Visible tumor on high b-value DWI reached a sensitivity and specificity for predicting prognostic group being highest at 5 weeks, 83 % (5/6) and 63 % (5/8), respectively. The combination of tumor size at baseline and visible tumor on DWI at 5 weeks, resulted in an area under the curve (AUC) = 0.83. At 12 weeks, no GP patients, but 2/7 PP patients showed visible tumor on DWI. Addition of ADC-values in the analysis did not improve the predictive value at any time point.

CONCLUSION: This pilot study indicates that the tumor size on baseline MRI, combined with tumor visibility on DWI at 5 weeks, may predict outcome of chemoradiotherapy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Fridsten S, Hellman K, Sundin A, et al. Timing of MRI for early treatment response prediction of chemoradiotherapy in uterine cervical cancer. Eur J Radiol. 2025. PMID: 41308571. doi:10.1016/j.ejrad.2025.112566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。